Novartis exec sold shares before drug data manipulation made public

VIENNA (Reuters) - An unnamed Novartis executive sold 925,400 Swiss francs (778,665 pounds) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated.Novartis announced the stock sale by an executive member of the board of directors or a member of the executive committee in a Swiss stock exchange filing dated July 19. The sale was first reported by Swiss newspaper SonntagsZeitung on..